



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Dynamic Optimization of a Fed-Batch Nosiheptide Reactor

Citation for published version:

Rodman, A, Diab, S & Gerogiorgis, D 2020, 'Dynamic Optimization of a Fed-Batch Nosiheptide Reactor', *Processes*, vol. 8, no. 5. <https://doi.org/10.3390/pr8050587>

Digital Object Identifier (DOI):

[10.3390/pr8050587](https://doi.org/10.3390/pr8050587)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Processes

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 Article

2 Dynamic Optimization of a Fed-batch Nosiheptide 3 Reactor

4 Alistair D. Rodman, Samir Diab, Dimitrios I. Gerogiorgis*

5 Institute for Materials and Processes (IMP), School of Engineering, University of Edinburgh, The King's
6 Buildings, Edinburgh, EH9 3FB, Scotland, UK; S.Diab@ed.ac.uk (S.D.)

7 * Correspondence: D.Gerogiorgis@ed.ac.uk (D.I.G.); Tel.: +44-131-651-7072

8 Received: date; Accepted: date; Published: date

9 **Abstract:** Nosiheptide is a sulfur-containing peptide antibiotic, showing exceptional activity against
10 critical pathogens such as Methicillin-Resistant *Staphylococcus Aureus* (MRSA) and Vancomycin-
11 Resistant *Enterococci* (VRE) with applications for livestock and can be synthesized via fed-batch
12 fermentation. A simplified mechanistic fed-batch fermentation model for nosiheptide production
13 from the literature considers temperature- and pH-dependence of biomass growth, substrate
14 consumption, nosiheptide production and oxygen mass transfer into the fermentation broth.
15 Herein, we perform dynamic simulation over a broad range of possible feeding policies to
16 understand and visualize the region of attainable reactor performances and productivities. We then
17 formulate a dynamic optimization problem for maximization of nosiheptide production for
18 different constraints of batch duration subject to operability constraints. A direct method for
19 dynamic optimization (simultaneous strategy) has been performed in each case to compute the
20 optimal control trajectories. Orthogonal polynomials on finite elements are used to approximate the
21 control and state trajectories allowing the continuous problem to be converted to a Nonlinear
22 Programme (NLP). The resultant large-scale NLP problem is solved using IPOPT. Optimal
23 operation requires feed rate to be manipulated in such a way that the inhibitory mechanism of the
24 substrate can be avoided, with significant nosiheptide yield improvement realized.

25 **Keywords:** Dynamic optimization; Nosiheptide; Fed-batch process; Pharmaceutical manufacturing

26

27 1. Introduction

28 1.1. Nosiheptide

29 Antibiotics are essential pharmaceutical products in modern society [1], whose syntheses either
30 require complex multistep chemical routes [2,3] or make use of enzymatic pathways [4] to obtain
31 their complex molecular structures. Designing efficient antibiotic manufacturing processes is
32 imperative. Nosiheptide (Figure 1), a sulfur-containing peptide antibiotic obtained through
33 fermentation, exerts exceptional antibiotic activity in vitro and in a mouse model against critical
34 Gram-positive pathogens such as Methicillin-Resistant *Staphylococcus Aureus* (MRSA), Vancomycin-
35 Resistant *Enterococci* (VRE) or *Clostridium difficile*. Nosiheptide and other thiopeptide's mechanism of
36 action is a result of binding on the 50S ribosomal subunit which prevents selective protein synthesis.
37 Shown non-toxic at high dosages, it is principally used for livestock applications [5]. Figure 2 shows
38 sales volumes of different antibiotic classes for livestock applications, with sulphur-containing
39 antibiotics (including nosiheptide) being one of the top sellers. Recently the first total synthesis of
40 nosiheptide was reported, utilizing double macro-cyclization of a fully functionalized linear
41 precursor [6]. Given low industrial yields, strong motivation exists to dynamically-optimize the
42 process for improved product yield while reducing production time and cost to improve the
43 industrial relevancy of manufacturing this promising antibiotic [7,8].





Figure 1. Nosiheptide molecular structure skeletal (left) + 3D (right) structures [9].

44
45

46 1.2. Process Modeling and Optimization Studies

47 Antibiotics are often produced via batch or fed-batch bioprocessing and frequently using
48 enzymatic pathways. Dynamic modeling, simulation and optimization are used for theoretical
49 understanding of complex reaction networks inherent of biopharmaceutical production and to
50 elucidate optimal control trajectories/operating policies to meet specific production targets (e.g.,
51 maximize yield subject to purity constraints) [10]. Human antibiotic production, particularly β -
52 lactams (whose broad applications + importance in global healthcare make them high priority), have
53 received a lot of attention in process systems engineering in the past decade; a summary of pertinent
54 literature examples on modeling and optimization of antibiotic production is provided in Table 1.



55
56

Figure 2. Sales of livestock antibiotics for by antibiotic class (top) and animal type (bottom) [11].

57

Table 1. Select modeling and optimization studies for human β -lactam antibiotic production.

Antibiotic	Application	Study	Ref.
Amoxicillin	Tonsillitis	Application of ANNs to model complex reaction scheme for	[12]
	Bronchitis	PGA catalyzed synthesis	
	Pneumonia	Inclusion of additional experimental data to improve ANN	[13]
	Gonorrhoea	in ref. [12].	
	Sinus infections	Maximization of API formation vs. different operating	[14]
	UTIs	conditions in either methanol / ethylene glycol as reaction	
		solvents	
		Sensitivity analysis on previous ANN study [12]	[15]
		Modeling + simulation of continuous reactive crystallization	[16,17]
		in presence of substrates and impurities	
		Dynamic optimization of non-isothermal reactor	[18]
Ampicillin	UTIs	Regression of nucleation and growth kinetics for pH	[19]
	Pneumonia	crystallisation model	
	Gonorrhoea	Modeling + simulation of reactive crystallization in presence	[20]
	Meningitis	of substrates and impurities	
	Abdominal	Modeling + simulation of continuous reactive crystallization	[16,17]
infections	in presence of substrates and impurities		
		Multiobjective dynamic optimization of pH crystallization	[21]
Cephalexin	UTIs	Non-isothermal modeling of enzymatic cephalixin batch	[22]
	Respiratory tract	synthesis	
	infections	Optimization of synthesis pH, temperature and	[23]
	Ear infections	concentrations	
	Skin infections	Non-isothermal modeling of enzymatic cephalixin batch	[24]
	synthesis		
		Modeling + simulation of reactive crystallization in presence	[16,17]
		of substrates and impurities	
		Regression of nucleation and growth kinetics for pH	[25]
		crystallisation model	

58

59

60

61

62

63

64

65

66

67

Modeling and optimization of fed-batch biopharmaceutical processes have also received significant attention for a wide variety of products, literature examples of which are summarized in Table 2. A variety of studies for the production of a range of products (including proteins, monoclonal antibodies (mAbs), antibiotics, amino acids etc.) from different biomass sources (including Chinese Hamster Ovary (CHO) cells for mAb production). Once reaction model parameters have been regressed (the subject of many different studies in Tables 1 and 2 and beyond), process model optimization subject to different design + operational constraints for different objectives (e.g., maximum productivity for composition limitations on purity) can be performed to realize the optimum design. Such studies have been implemented frequently for batch/fed-batch process development (Table 2).

68

1.3. This Work

69

70

71

72

73

74

75

76

77

78

A fed-batch fermentation process dynamic model for nosiheptide production described by Niu and colleagues (2013,2016) [26,27] allows insight into the process design space + elucidation of optimal feeding policies for enhanced productivity, which is yet to be done for this antibiotic; therein lies the novelty of the work. This paper is structured as follows: First, the published dynamic fed-batch model equations are described with model parameter estimation performed to improve process model accuracy vs. published experimental data; dynamic simulation is performed to understand the region of attainable fermentor performances; a dynamic optimization problem is then formulated and solved to elucidate the optimal reactor feeding policy to enhance the production of nosiheptide. A critical discussion of the simulation and optimization methodologies is also provided vs. the available data used for formulation and outlook on the field.

79

Table 2. Select modeling and optimization studies for fed-batch pharmaceutical production.

No.	Product		Biomass	Substrate	Objectives	Observations	Lit. Ref.
	Molecule	Application					
1	Podophyllotoxin	Anticancer	<i>Podophyllum hexandrum</i>	Indoleacetic acid, Glucose, Oxygen	Regress model parameters from batch data to inform fed-batch design	Increased volumetric productivity by 35.8%.	[28]
2	Unnamed protein	Unknown	Unnamed	Glucose, Oxygen	Application of ANNs to model bioprocess	ANN formulated to capture industrial process behaviour.	[29]
3	Fluoroleucine ethyl ester	Pharmaceutical intermediate	<i>Candida antarctica</i>	Az lactone, Ethanol	Kinetic parameter regression for fed-batch process optimization	400% increase in fed-batch mode productivity vs. batch operation	[30]
4	Glutamine	Amino acid	CHO cells	Glucose, Oxygen	Markov chain Monte Carlo method for kinetics modeling	Fed-batch process modeling in 5,000 L bioreactor	[31]
5	Butyric acid	Histamine antagonist	<i>Clostridium tyrobutyricum</i>	Glucose, Oxygen	Reaction kinetic model parameter regression for fed-batch process	Increased productivity + growth with fed-batch operation	[32]
6	Penicillin	Antibiotic	<i>Penicillium</i>	Glucose, Oxygen	Implementation of Design of Dynamic Experiments for process optimization	Process optimization with few experiments	[33]
7	mAb	Various therapeutic applications	GS-NS0 cell line	Glucose	Sensitivity analysis + dynamic optimization	Increased productivity	[34]
8	EG2-hFc (mAb)	Various therapeutic applications	CHO cells	Glucose, Oxygen	Reaction kinetic parameter regression + sensitivity analysis	Single set of parameters described state trajectories	[35]
9	Unnamed mAb	Various therapeutic applications	CHO cells	Glucose, Oxygen	Reaction kinetic parameter regression for modeling	System modeling on lab- and production scales	[36]
10	β -Carotene	Vitamin A precursor	<i>Saccharomyces cerevisiae</i>	Glucose, Ethanol, Oxygen	Dynamic optimization of reaction scheme	Reduced operating costs of bioreactor	[37]
11	mAb	Various therapeutic applications	GS-NS0 cells	Glucose, Glutamine	Model reformulation to improve computational efficiency	Improved structure and increased production from optimal feeding	[38]
12	Immunoglobulin G (mAb)	Various therapeutic applications	CHO cells	Unspecified	Dynamic model formulation for optimal pH control	Increased productivity from optimal control	[39]
13	mAb	Various therapeutic applications	GS-NS0 cells	Glucose, Glutamine	Comparison of simultaneous + sequential optimization	Sequential approach attains higher productivity	[40]

80

2. Dynamic Process Modeling, Simulation and Optimization Methodology

81

2.1. Nosiheptide Fed-Batch Fermentation Model + Parameter Estimation

82

2.1.1. Dynamic Process Model

83

A schematic of the fed-batch fermentation process for nosiheptide is shown in Figure 3 [26,27].

84

The bioreactor/fermentor has volume, $V_F = 100$ L with biomass (*Streptomyces actuosus*) in broth

85

volume, $V = 60$ L at the start of the batch (time, $t = 0$). Varying the reactor feeding (F), temperature (T)

86


and pH alter state profiles over the batch duration, namely biomass (X), substrate (S), product (P) and

87

dissolved oxygen (CO) concentrations. The subsequent dynamic fed-batch process model assumes

88

ideal mixing and no lag with respect to changes in process conditions during the batch.



89

 V_F

90

Figure 3. Fed-batch nosiheptide production via fermentation.

91

The fed-batch fermentation of *Streptomyces Actuosus* to produce nosiheptide is a complex biochemical process. The dynamic process model makes various simplifications in order to simplify the model equations [26,27]. The model assumptions include (1) ideal mixing such that pH , T and concentrations (X , S , P) are spatially uniform in the bioreactor at a given t , (2) biomass cell chemical compositions do not vary with t and (3) there is negligible lag between the imposed fermentation process condition changes and process dynamics.

97

The dynamic model for nosiheptide fermentation is that proposed by Niu and colleagues (2013,2016) and references therein [26,27]; The main objectives of this study are parameter estimation to improve model discrepancy vs. reporter experimental results by the same authors and to then perform dynamic optimization of the fed-batch fermentation process to elucidate possible improvements for nosiheptide production.

102

Biomass (X) growth is defined by specific growth (μ_g) and death (μ_d) rates (functions of both pH and temperature, T). In Eq. 1, the first term = cell growth, second term = cell death and third term = dilution by reactor feed, respectively. Here, F = reactor feed flow rate, V = culture volume, A_g and A_d = pre-exponents for growth and death terms, respectively, E_g and E_d = energy barriers to growth and death, respectively, R = Universal gas constant, K_1 and K_2 = model constants, K_s and K_o = the substrate and oxygen Contois saturation constants, respectively, K_d = the Monod constant, CO = dissolved oxygen content and X_{MAX} = maximum biomass concentration.

108

$$\frac{dX}{dt} = \left(\mu_g - \mu_d - \frac{F}{V} \right) X \quad (1)$$

$$\mu_g = \frac{A_g \exp\left(-\frac{E_g}{RT}\right)}{1 + \frac{K_1}{10^{pH}} + \frac{K_2}{CO}} \frac{S}{K_s X + S} \frac{CO}{K_o X + CO} \left(1 - \frac{X}{X_{MAX}}\right) \quad (2)$$

$$\mu_d = A_d \exp\left(-\frac{E_d}{RT}\right) \left(1 - \frac{CO}{K_d + CO}\right) \quad (3)$$

109

The substrate (S) is considered to have three actions, described by each term in Eq. 4: to provide nutrients for cell growth (first term), to produce metabolites (second term) and to maintain bacteria culture activity (third term), with the fourth term describing dilution from the reactor feed. Here, m_s = the maintenance coefficient of substrate and $Y_{X/S}$ and $Y_{P/S}$ = the yield constants of biomass and product vs. substrate, respectively.

113

$$\frac{dS}{dt} = -m_s X - \frac{1}{Y_{X/S}} \frac{dX}{dt} - \frac{1}{Y_{P/S}} \frac{dP}{dt} - \frac{F}{V} X \quad (4)$$

114 The Luedeking-Piret model for microbial metabolite formation (i.e., nosiheptide production) is
 115 considered, simplifying to account for the rate being uncoupled with cell growth (i.e., nosiheptide
 116 production is independent of cell growth rate), producing Eq. 5, where K_h = the equilibrium constant,
 117 β = specific production rate (Eq. 6), μ_P = specific production rate and K_P and K_I = production rate
 118 inhibition constants

$$\frac{dP}{dt} = \beta X - K_h P - \frac{F}{V} P \quad (5)$$

$$\beta = \frac{\mu_P S}{K_P + S + \frac{S^2}{K_I}} \quad (6)$$

119 The reaction volume, V , increased over time with the feed-rate, F . The model assumes a dilute
 120 fermentation broth with negligible volume changes due to biomass growth, substrate consumption
 121 or nosiheptide formation.

$$\frac{dV}{dt} = F \quad (7)$$

122 A dissolved oxygen model is considered from a mass balance (Eq. 8, [26,27]). The saturated
 123 oxygen concentration, CO^* , is a function of temperature and is reported with a value of 0.037 g L^{-1} in
 124 the fermentation broth in the original experimental demonstration [26,27]; it is assumed that this
 125 value does not vary with changing state profiles over the course of the batch duration. The volumetric
 126 transfer coefficient (K_{La}) is dependent on the tank and stirrer characteristics as defined by Eq. 10. In
 127 Eq. 8, the first term ($K_{La}(CO^* - CO)$) = mass transfer of oxygen into the fermentation broth, the second
 128 term ($m_O X$) = biomass maintenance consumption, the third term ($\frac{1}{Y_{X/O}} \frac{dX}{dt}$) = oxygen consumption due
 129 to biomass growth, the fourth term ($\frac{1}{Y_{P/O}} \frac{dP}{dt}$) = oxygen consumption in product formation and the
 130 fifth term ($\frac{F}{V} CO$) describes dilution from reactor feed. Here, CO^* = saturation dissolved oxygen
 131 concentration, m_O = maintenance coefficient of dissolved oxygen, $Y_{X/O}$ and $Y_{P/O}$ = yield constants of
 132 biomass and product vs. dissolved oxygen, respectively, d = agitator diameter, n = agitator speed, P_i
 133 = input power under nonaerobic conditions, Q = ventilation volume and D = vessel volume.

$$\frac{dCO}{dt} = K_{La}(CO^* - CO) - m_O X - \frac{1}{Y_{X/O}} \frac{dX}{dt} - \frac{1}{Y_{P/O}} \frac{dP}{dt} - \frac{F}{V} CO \quad (8)$$

$$CO^*(T = 29 \text{ }^\circ\text{C}) = 0.037 \text{ g L}^{-1} \quad (9)$$

$$K_{La} = 0.1322 \frac{d^{0.56} n^{0.18} P_i^{0.36} Q^{0.3992}}{DV^{0.4}} \quad (10)$$

134 2.1.2. Model Parameter Estimation

135 Niu and colleagues (2013,2016) performed a range of experimental campaigns, gathering state
 136 data to facilitate parameter estimation of values which may not be directly measured [26,27]. It was
 137 found that there was significant mismatch between certain presented state trajectories (namely
 138 product P and dissolved oxygen content CO) and those resulting from simulating the model using
 139 the entire published parameter set (29 parameters). As a result, a selective parameter re-estimation
 140 has been performed for 5 parameters, which pertain to uptake ratios for oxygen consumption (m_O
 141 and $Y_{X/O}$) and product formation (μ_P , K_h , $Y_{P/O}$). MATLAB's OPTI Toolbox and the *fmincon* function is
 142 used to minimize the error between state trajectories and the experimental data (Eq. 11), solving for
 143 the parameter vector, $\theta = [m_O \ Y_{X/O} \ \mu_P \ K_h \ Y_{P/O}]$, giving the best fit.

$$\min_{\theta} \sum_i \sum_j \left(\frac{\text{data} - \text{model}}{\text{data}_i} \right)^2 \quad (11)$$


144

Table 3. Dynamic model kinetic (published + regressed in this study) + fermentor design parameters.

<i>Kinetic Parameters</i>				
Parameter Description	Symbol	Value	Units	Source
Growth pre-exponent	A_g	0.1224	hr ⁻¹	[27]
Growth energy barrier	E_g	60	kJ mol ⁻¹	[27]
Death pre-exponent	A_d	1.9×10 ⁻³	hr ⁻¹	[27]
Death energy barrier	E_d	340	kJ mol ⁻¹	[27]
Eq. 2 constant	K_1	1×10 ⁻¹⁰	(-)	[27]
Eq. 2 constant	K_2	1.3×10 ⁻⁴	(-)	[27]
Substrate Contois constant	K_s	0.1828	g L ⁻¹	[27]
Oxygen Contois constant	K_o	0.0352	g L ⁻¹	[27]
Max. substrate concentration	X_{MAX}	0.87	g L ⁻¹	[27]
Monod constant	K_d	0.0368	(-)	[27]
Hydrolysis constant	K_h	4.0×10 ⁻⁴	hr ⁻¹	This study ^a
Substrate maintenance coefficient	m_s	0.0624	g g ⁻¹ hr ⁻¹	[27]
Biomass/substrate yield constant	$Y_{X/S}$	0.25	g g ⁻¹	[27]
Product/substrate yield constant	$Y_{P/S}$	0.68	g g ⁻¹	[27]
Specific production rate	μ_P	0.05	g g ⁻¹ hr ⁻¹	This study ^a
Production inhibition constant	K_i	0.1	g L ⁻¹	[26]
Production inhibition constant	K_P	2×10 ⁻⁴	g L ⁻¹	[26]
Oxygen maintenance coefficient	m_o	4.0×10 ⁻³	g g ⁻¹ hr ⁻¹	This study ^a
Biomass/oxygen yield constant	$Y_{X/O}$	43.5	g g ⁻¹	This study ^a
Product/oxygen yield constant	$Y_{P/O}$	253.3	g g ⁻¹	This study ^a
<i>Design Parameters</i>				
Parameter Description	Symbol	Value	Units	Source
Fermentor volume	V_F	100	L	[26,27]
Ventilation rate	Q	3.0	m ³ hr ⁻¹	[26,27]
Agitation speed	n	400	rpm	[26,27]
Stirring power	P	1,500	W	[26,27]
Agitator diameter	d	0.01	m	[26,27]
Vessel diameter	D	0.5	m	[26,27]
^a Quality of parameter fit: Niu et al. (2013,2016) [26,27] vs. this study.				
Variable	MSE		SSE	
	Niu et al. (2013,2016) [26,27]	This study	Niu et al. (2013,2016) [26,27]	This study
Product, P	4.940×10 ⁻¹	6.815×10 ⁻⁵	8.398	1.158×10 ⁻³
Dissolved Oxygen, CO	3.700×10 ⁺³	4.280×10 ⁻⁵	6.290×10 ⁺⁴	0.728×10 ⁻³

145 The model fit to P and CO profiles vs. experimental data is greatly improved following
 146 parameter regression of θ , as shown in Figure 4. The model kinetic parameter values (both fitted and
 147 taken from the literature) are listed in Table 3. Design parameters of the bioreactor are taken as those
 148 considered in the literature and are also summarized in Table 3. The improved model fit in product
 149 and dissolved oxygen concentrations are also quantified in Table 3 by their corresponding Mean
 150 Squared Error (MSE) and Sum of Squared Errors (SSE) values for P and CO profiles.

151 All model parameters are taken from studies by Niu and colleagues (2013,2016) on the same
 152 experimental apparatus, where errors of their parameter fits on different species concentrations are
 153 also reported [26,27]. Our parameter regression showed reduced discrepancy between the
 154 experimental and model results. It is important to validate all results presented in this work (both
 155 model parameter estimates and dynamic optimization runs) vs. further experimental runs on the
 156 apparatus used by Niu and colleagues (2013,2016) [26,27].



157

158

159

Figure 4. Modeled vs. experimental product concentrations from (a) published model [26,27] and (b) this work and dissolved oxygen concentrations from (c) published model [26,27] and (d) this work.

160

2.2. Dynamic Simulation

161

162

163

164

165

166

167

168

169

170

171

172

173


174

175

176

177

Exploring the entire dynamic operating design space with respect to attainable productivity and reactor performance is useful in order to understand in depth the biochemical system behavior prior to undertaking dynamic optimization [41]. We implement exhaustive dynamic simulation subject to rules and constraints on the possible control (reactor feedrate) profiles over the batch duration to limit the number of simulations + total computational effort [41]. A total possible batch duration of $t_f = 96$ hr is considered (as per the experimental demonstrations [26,27]). The control profiles are considered Piecewise Constant (PWC) with six temporal elements ($N = 6$) considered, i.e., a time step of $\Delta t = 16$ hr. The reactor feed can have initial values considered, $F(t = 0) = 0.1 : 0.1 : 0.9$ L hr⁻¹, i.e., nine (9) possible starting values. After each Δt , the change in reactor feed, $\Delta F = \{0, \pm 0.1, \pm 0.2, \pm 0.3, \pm 0.4\}$ L hr⁻¹; profiles which result in $F(t) < 0$ or $F(t) > 1$ (= feed rate bounds), as well as cases where $V(t) > 100$ (= fermentation vessel volume) are not considered to respect the bounds imposed as per the experimental demonstration [26,27]. Figure 5 shows an example of two possible reactor feedrate profiles considered within the dynamic simulation, with all of the abovementioned restrictions met. The resulting number of feed profiles considered for dynamic simulation = 625,331. The effects of different feed profiles on state variables and different trade-offs therein are then considered. Thereafter, mathematical dynamic optimization is performed in order to elucidate the optimal reactor feedrate policy to maximize nosiheptide production.



178

179

Figure 5. Sample dynamic simulation reactor feedrate profiles.

180 2.3. Dynamic Optimization

181 2.3.1. Problem Statement

182 Determining how any industrial production process shall be operated efficiently typically
 183 involves mathematical optimization in some form [42]. Often this will include an optimal control
 184 problem, where a system of state variables $[x]$ are influenced by an externally manipulated control
 185 variable, u , so the optimal control vector $u(t)$ is sought to minimize an objective, φ . Considering a
 186 generic problem where no running payoff is considered (objective, Eq. 12, evaluated at terminal time
 187 only), the dynamic optimization problem can be defined as follows [43,44].

$$\min_{u(t), t_f} \varphi(x(t_f), t_f) \quad (12)$$

$$\frac{dx}{dt} = f(x(t), u(t)) \quad (13)$$

$$x(t_0) = x_0 \quad (14)$$

$$h(x(t), u(t)) = 0, g(x(t), u(t)) \leq 0 \quad (15)$$

$$h_f(x(t_i)) = 0 \quad (16)$$

$$g_f(x(t_i)) \leq 0 \quad (17)$$

$$u_L \leq u(t) \leq u_U \quad (18)$$

$$x_L \leq x(t) \leq x_U \quad (19)$$

188 The Ordinary Differential Equations (ODEs) which dictate the state trajectories (Eq. 13) are
 189 influenced at any time by the current control (u) value, with initial state conditions given by Eq. 14.
 190 Eqs. 3 and 4 represent equality and inequality constraints respectively across the entire time horizon,
 191 $t \in [t_0, t_f]$, with terminal constraints given by Eqs. 16 and 17. Lastly, the state and control boundaries
 192 are constrained within permissible bounds by Eqs. 18 and 19.

193 2.3.2. Solution Method

194 A wide range of methodologies exist for solving an optimal control trajectory problem, including
 195 variation methods and finite approximation methods [41,45]. In the former exploiting Pontryagin's
 196 maximum principle allows the resulting two-point boundary value problem to be solved, while the
 197 latter uses predefined functional forms to represent the control profile [46]. Finite formulations may
 198 be tackled with simultaneous, sequential or multi shooting strategies which are extensively reviewed
 199 in the literature [43]. The sequential strategy involves discretisation of the control profile with the
 200 ODE system (process model), requiring regular re-integration during the algorithm to compute
 201 corresponding state trajectories, an approach effective for problems with few decision variables and

202 constraints [47], which has been widely applied to engineering problems [48–50]. In contrast,
 203 simultaneous strategies require the ODE system to also be discretized on the time horizon to produce
 204 a large-scale Nonlinear Programming (NLP) problem requiring no further integration of the
 205 Differential Algebraic Equation (DAE) system, generally using orthogonal collocation techniques.
 206 The later offers numerous benefits, being faster to solve and able to handle problems with a greater
 207 number of decision variables and constraints [51,52].

208 A direct method for dynamic optimization (simultaneous strategy) is performed. Orthogonal
 209 polynomials on finite elements are used to approximate the control and state trajectories, allowing
 210 the continuous problem to be converted to NLP form. The DAE system is converted to a system of
 211 Algebraic Equations (AEs), where decision variables of the derived NLP problem are the coefficients
 212 of the linear combinations of these AEs. Precision varies with collocation point locations and step
 213 sizes used [53,54].


214 Consider the general problem with N elements ($i = 1, \dots, N$), each of which has K collocation points
 215 ($j = 1, \dots, K$). The differential profiles (Eq. 13) can be approximated by Eq. 20, where Δt_i is the length
 216 of element i and $dx/dt_{i,j}$ is the derivative of the state variable in element i at the j^{th} collocation point.
 217 Ω_j is a j^{th} order polynomial satisfying Eq. 21. Continuity of the state trajectories is ensured by Eq. 22.
 218 The control profile is approximated by Eq. 23, where ψ_j is a Lagrange polynomial of degree K that
 219 satisfies $\psi_j(\rho_j) = \delta_j$ for $j = 1, \dots, K$. It is shown in Figure 6 how control variables may have discontinuities
 220 at element boundaries, while continuity in states at these same boundaries is produced. In doing so,
 221 the continuous general problem has been reduced to a discreet DAE system, which can be solved by
 222 a suitable NLP subroutine.

$$x_i = x_{i-1} + \Delta t_i \sum_{j=1}^K \Omega_j \left(\frac{t - t_{i-1}}{\Delta t_i} \right) \frac{dx}{dt_{i,j}} \quad (20)$$

$$\Omega_j(0) = 0, \quad \Omega'_j(\rho_j) = \delta_j \quad \text{for } j = 1, \dots, K \quad (21)$$

$$x(t) = x_{i-1} + \Delta t_i \sum_{j=1}^K \Omega_j(1) \frac{dx}{dt_{i,j}} \quad (22)$$

$$u(t) = \sum_{j=1}^K \psi_j \left(\frac{t - t_{i-1}}{\Delta t_i} \right) u_{i,j} \quad (23)$$



223

224 **Figure 6.** Collocation method for state and control profiles (based on Biegler, 2007 [44]).

225 2.3.3. Optimization Objectives and Strategy

226 There are two obvious objectives for optimal fermentation: reduced duration and maximum
 227 productivity (even if this requires later dilution, it is desirable to enhance yield). A bi-objective
 228 problem is considered, defined by Eqs. 24–26. Multiple optimization objectives can also be

229 formulated as a single objective function by considering a sum of weighted individual objectives as
 230 in other studies by our group [41]; however, such methods can be used studies considering full-scale
 231 industrial operation with ample experimental and dynamic production data acquisition, whereas for
 232 comparison of modeling and optimization results vs. a relatively small experimental dataset (as is
 233 the case here), a bi-objective problem defined as a product of individual process objectives is more
 234 appropriate. Operability and model constraints impose bounds on the control profiles (Eqs. 27–29) as
 235 well as the total volume being limited by the reactor size (Eq. 30).

$$\min_{T(t), pH(t), F(t)} f_1 f_2 \quad (24)$$

$$f_1 = t_i \quad (25)$$

$$f_2 = -V(t_i) P(t_i) \quad (26)$$


$$299 \leq T(t) \leq 305 \quad \text{for } t \in [t_0, t_i] \quad (27)$$

$$6 \leq pH(t) \leq 8 \quad \text{for } t \in [t_0, t_i] \quad (28)$$

$$0 \leq F(t) \leq 1 \quad \text{for } t \in [t_0, t_i] \quad (29)$$

$$V(t) \leq 100 \quad \text{for } t \in [t_0, t_i] \quad (30)$$


236 To elucidate the sensitivity of the model states on manipulated controls (F , T , pH), a sensitivity
 237 analysis was performed. Figure 7 shows the effect of varying constant reactor pH on state profiles,
 238 showing negligible variation over the applicable pH range = 6–8 (Eq. 28); this is due to the pH-
 239 dependent model term (Eq. 2) varying weakly vs. pH for the given model parameters (K_1 and K_2).
 240 Similarly, the sensitivity of states vs. isothermal reactor temperature ($T(t) = 26\text{--}32\text{ }^\circ\text{C}$) are compared
 241 in Figure 8. The variation in states vs. temperature is also negligible due to biomass cell growth and
 242 death (numerators of first terms in Eqs. 2 and 3, respectively) varying weakly vs. temperature within
 243 the applicable range. The model dependence of both temperature and pH is as presented in the
 244 literature [26,27]. We illustrate effects to justify selection of only reactor feeding as manipulation
 245 variable for dynamic optimization. It is possible that the growth peak occurs at a higher temperature
 246 than the range of values considered here (bounds chosen to ensure model parameters are
 247 commensurate with experiments), which should be confirmed via experiments in the same apparatus
 248 as that described by Niu and colleagues (2013,2016) [26,27].



249

250

Figure 7. Effect of varying $pH(t) = \text{constant}$ (a) on (b) biomass, (c) substrate and (d) product concentrations.



251

252

Figure 8. Effect of varying $T(t) = \text{constant}$ (a) on (b) biomass, (c) substrate and (d) product concentrations.

253

254

255

256

257

The results of the sensitivity analysis imply that it is logical to remove temperature and pH profiles from the optimization problem to reduce the problem size compared to optimizing all three controls simultaneously. Reactor temperature and pH are fixed as per the literature (see Table 4) to ensure healthy biomass and allowing the feed profile to be optimized in isolation. Initial conditions for state variables are assumed to be as in the literature and are also summarized in Table 4.

258

Table 4. Fixed operating + initial state conditions as per the original experimental study [26,27].

<i>Operating Variable</i>				
Variable	Symbol	Initial Value	Units	
Temperature	$T(t_0) = T(t)$	30	°C	
pH	$pH(t_0) = pH(t)$	7	(–)	
<i>State Initial Condition</i>				
Variable	Symbol	Initial Value	Units	
Biomass loading	$X(t_0)$	0.05	g L ⁻¹	
Substrate	$S(t_0)$	40	g L ⁻¹	
Product	$P(t_0)$	0	g L ⁻¹	
Culture volume	$V(t_0)$	60	L	
Dissolved oxygen	$CO(t_0)$	0.037	g L ⁻¹	

259

260

261

262

263

264

265

266

267

268

269

270

271

Any multi-objective problem, such as the one defined by Eq. 24, will not have a single solution, but rather an entire optimal front upon which no single objective can be improved without sacrificing another, i.e., a Pareto front. Numerous approaches can be used to modify a multi-objective problem for compatibility with single objective methods such as that proposed in Section 2. Commonly, a weighted sum objective is used to combine the competing objectives into a single term with weights defining the relative importance of each. However, weights assigned to the multiple process targets to produce a single objective function may be considered arbitrary, with decision-makers not necessarily able to quantify *a priori* the relative importance of the competing objectives. Rather, we elect to consider a ε -constraint approach. One of the objectives can be considered as a constraint in the problem formulation, solving the other to optimality. This is repeated, increasing the value of the objective ε -constraint and resolving. Repeating this process by incrementally increasing the ε -constraint value across the entire span of permissible values for that objective. Here, the batch time is treated as the secondary objective and converted to a constraint (Eqs. 33 and 34).

$$\min_{F(t)} -V(t) P(t) \quad (33)$$


$$t_f = \varepsilon \quad (34)$$

272 Solving this modified problem across a range of values for ε produces a Pareto front of optimal
 273 solutions, allowing the trade-off to be visualized and used for process design and operation decisions.
 274 Generally, Eq. 34 would be an inequality constraint in the ε -constrained multi-objective method;
 275 however, as to visualize the performance drop observed in excessively long batches an equality term
 276 is used. Doing so enforces the specific batch time in each case, in place of converging to the optimal
 277 batch length with little indication of the responsible mechanism. We consider $\varepsilon = \{120, 200, 205, 275,$
 278 $390\}$ hr and varying $N = 20$.

279 3. Results and Discussion

280 3.1. Dynamic Simulation and Design Space Visualization

281 Figure 9 presents trade-offs between different state variables from the range of reactor feedrate
 282 profiles for dynamic simulation purposes. The following comparisons are made: product vs.
 283 remaining biomass, volume vs. biomass, product and biomass vs. dissolved oxygen and product vs.
 284 fermentation broth volume and total amount of fed material during fed-batch production ($= \sum F(t)\Delta t$).
 285 Various trade-offs and trends between states are observed.



286

287

288

289

290

Figure 9. Trade-offs at end of batch duration for different reactor feedrate profiles ($t_f = 96$ hr): (a) Product vs. Biomass concentrations, (b) Culture volume vs. Biomass concentration, (c) Product vs. Dissolved oxygen concentrations, (d) Biomass vs. Dissolved oxygen concentrations, (e) Product concentration vs. Culture volume, (f) Product concentration vs. amount of fed material.

291 Observing the attained product concentrations vs. biomass at the end of the batch duration
292 shows that the highest productivities are attained from intermediate biomass values, not necessarily
293 from the highest. It is also observed that many of the considered reactor feedrate profiles achieve
294 comparably low productivities for their given biomass present, highlighting the need for process
295 optimization. Resulting broth volumes are also highest at the low to intermediate range of biomass
296 concentrations; it should be noted that the model assumes that biomass growth does not affect broth
297 volume, i.e., that the system is relatively dilute. For adaptation to systems with higher biomass
298 loading, Eq. 7 should contain a term that describes volumetric changes due to biomass growth.

299 Biomass concentrations are highest when the system is near oxygen saturation due to cells
300 requiring oxygen for growth. Most of the considered reactor feedrate profiles approach oxygen
301 saturation; however, the maximum productivities are obtained for profiles with lower dissolved
302 oxygen content. It is also observed that the highest product concentrations are observed for
303 intermediate values of reactor feedrates/final broth volumes. Banding is observed in the product vs.
304 volume/fed material plots due to the discreet initialized values and step changes considered for
305 dynamic simulation purposes (see Section 2.2).


306 Figure 9 shows that the highest nosiheptide product concentrations are attained with very
307 particular reactor feedrate profiles, i.e., the system performance is very sensitive to the considered
308 reactor feedrate profiles. The results of this design space investigation + visualization via dynamic
309 simulation provides an incentive for dynamic optimization to systematically establish the optimum
310 feed profile. The dynamic simulation results show performances attained for $t_f = 96$ hr (i.e., batch
311 duration considered in the experimental studies [26,27]) only; observing the effect of varying batch
312 time is also considered as part of the dynamic optimization.

313 3.2. Optimal Reactor Reactor Feedrate Policy

314 The resultant large-scale NLP problem from DynOpt is solved for each instance using IPOPT
315 (Interior Point OPTimizer) [51,52] and global optimality is ensured with a multi-start search via Latin
316 Hypercube Sampling of the input space for initialization. Analytical state and control Jacobians in
317 addition to the objective gradients are explicitly defined and input to the solver which drastically
318 improves runtime due to far fewer function evaluations being required. The problem defined by Eqs.
319 36 and 37 has been solved for a range of instances, considering an array of initialization strategies
320 (initial control profile 'guesses') as well as for increasing time domain discretization, defined by the
321 number of control segments, N . Solution attainment is demonstrated as robust with little sensitivity
322 to the initialization strategy employed, as has been in the case in other dynamic simulation +
323 optimization studies on biochemical systems implemented by our group [55]. The performance of the
324 IPOPT NLP solver was compared to the default solver within MATLAB's OPTI Toolbox (*fmincon*),
325 with IPOPT equalling or outperforming in all instances. The single objective solution is shown in
326 Figure 10 where $N = 12$ and batch time $t_f = 120$ hr.

327 It is demonstrated that optimal feed trajectory computed is a novel parabolic form. This efficient
328 strategy initially feeds substrate at a high rate, assisting with the biomass development towards its
329 maximum value. Lowering this over the first portion of the process prevents restrictive dilution of
330 both the biomass and the early product formation. After sustaining a feed rate near 0.2 g L^{-1} until the
331 maximum biomass concentration is approached, the feed rate is increased exponentially towards the
332 end of the process, capitalizing on the reduced inhibition given that less substrate is now present in
333 the broth. It is noteworthy that the solution suggests the reactor should only be entirely full ($V = 100$
334 L) at the very end of the process. The multi-objective Pareto front of optimal solutions are presented
335 in Figure 11 where batch time as a secondary objective was constrained by increments of 5 hr between
336 100 and 400 hr according to Eq. 37.

337



338

339

340

Figure 10. Optimal feed profile (a) and corresponding model states, $\varepsilon = 120$ hr: (b) Culture volume, concentrations of (c) Biomass, (d) Substrate, (e) Product, (f) Dissolved oxygen.

341

342

343

344


345

346

347

348

Three distinct regions on the Pareto plot can be identified. In the left most, region (100–200 hr) a near linear relationship exists between attainable product mass and permitted batch time. Once batch time $t_f > 200$ hr a dramatic shift is observed, whereby a much larger product mass is produced. This continually increases at a less than linear rate until a maximum production is observed when the $t_f \approx 330$ hr. After this a dramatic drop in production is shown when batch time is excessively long. To better understand these observed trends, solution profiles of the model states corresponding to the solutions on the Pareto plot can be inspected. Figure 12 represents the solution for the scenario $t_f = 200$ hr, with the same for $t_f = 205$ hr shown in Figure 13.



349

350

Figure 11. Product mass vs. batch time Pareto front ($N = 12$).




Figure 12. Optimal feed profile (a) and corresponding model states, $\epsilon = 200$ hr: (b) Culture volume, concentrations of (c) Biomass, (d) Substrate, (e) Product, (f) Dissolved oxygen.

351
352
353

354 Figure 12 shows similar behaviour to Figure 10: initially promoting biomass growth before
355 lowering the feed rate for the intermediate batch portion, prior to increasing substrate feed to
356 capitalise on the favourable reactor state. The large transition in Figure 10 may be understood from
357 the $t_f = 205$ hr solution (Figure 13). This represents the first time at which the initial reactor substrate
358 content is completely consumed. This allows the substrate to deplete (feeding biomass growth and
359 maintenance), and the moment that the substrate concentration approaches zero the feed rate is
360 drastically increased. In doing so there is essentially no inhibitory mechanism and extremely efficient
361 fermentation may be performed for the remainder of the batch, generating an elevated mass of
362 product. This is similarly observed in Figure 14 for $\epsilon = 275$ hr, with a sustained feed period at the end
363 of the process at a precise level to prevent accumulation while still feeding rapid product growth.





Figure 13. Optimal feed profile (a) and corresponding model states, $\epsilon = 205$ hr: (b) Culture volume, concentrations of (c) Biomass, (d) Substrate, (e) Product, (f) Dissolved oxygen.


364
365
366



367
368
369

Figure 14. Optimal feed profile (a) and corresponding model states, $\varepsilon = 275$ hr: (b) Culture volume, concentrations of (c) Biomass, (d) Substrate, (e) Product, (f) Dissolved oxygen.

370 Figure 15 highlights the mechanism for the performance drop once the batch time becomes
371 excessively long. Here the batch time is too long for the finite reactor volume and substrate mass that
372 may be fed. Now the product hydrolysis becomes prohibitive with the nosiheptide produced earlier
373 being later consumed in the reaction timeframe, where overfilling the reactor would be necessary to
374 maintain a production rate greater than the hydrolysis rate in the late stages of the process. As such
375 a critical batch time is identified, after which yield is reduced. This also highlights that the product
376 state must be rapidly changed once the maximum production is observed, to prevent undesirable
377 product losses.



378
379
380

Figure 15. Optimal feed profile (a) and corresponding model states, $\varepsilon = 390$ hr: (b) Culture volume, concentrations of (c) Biomass, (d) Substrate, (e) Product, (f) Dissolved oxygen.

Care must be taken when interpreting these results. The optimal scenario appears to be to promote biomass growth prior to depleting the substrate concentration entirely, after which further substrate additions may be instantly converted to nosiheptide in the absence of an accumulated inhibitory substrate content in the reactor. While the model authors do not suggest the model is not valid under these conditions, the portion of their data used in the parameterization, which is presented in the corresponding publications, do not show such behaviour. The model validity under these conditions (no substrate accumulated) must first be ensured. The considered dynamic fed-batch fermentation model for nosiheptide production was developed by Niu and colleagues (2013,2016) and based on their experimental setup [26,27]. While experimental runs are out with the scope of this study, it is important to validate regressed model parameters and corroborate dynamic optimization results presented here with experimental campaigns of the pilot fermentation process.

5. Conclusions

The fed-batch production of nosiheptide is considered to circumvent mass transfer inhibition at excessive substrate concentrations in the reactant broth, where the reactor is only partially filled initially and substrate supplemented over time. Design space investigation and visualization via dynamic simulation of a large set of possible reactor feedrate profiles illustrated trade-offs and the need for systematic dynamic optimization due to the high process sensitivity to the chosen reactor feedrate policy. Dynamic optimization has been performed for minimization of batch time and inverse yield (for maximization). A ϵ -constraint approach has been implemented, treating batch time as a secondary objective which is converted to an inequality constraint that is gradually relaxed as the problem is re-solved to maximize nosiheptide production. Orthogonal polynomials on finite elements are used to approximate the control and state trajectories allowing the continuous problem to be converted to NLP form. Optimal operation requires the feed rate to be manipulated in such a way that the inhibitory mechanism of the substrate can be avoided; however, the model validity under these conditions (no substrate accumulated) must first be ensured to realize these results.

Author Contributions: Conceptualization, all authors; methodology, all authors; software, A.D.R.; validation, A.D.R.; formal analysis, all authors; writing, all authors; supervision, D.I.G.

Funding: A.D.R. acknowledges the Eric Birse Charitable Trust for a Doctoral Fellowship. S.D. and D.I.G. both acknowledge the support of the Great Britain Sasakawa and Nagai Foundations. S.D. acknowledges the Engineering and Physical Sciences Research Council (EPSRC) for a Doctoral Training Partnership Fellowship (Grant #EP/N509644/1). D.I.G. acknowledges a Royal Academy of Engineering (RAEng) Industrial Fellowship.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the study. Tabulated and cited literature data suffice for the reproduction of all original results and no other supporting data are required to ensure reproducibility.

Nomenclature

Acronyms

AE	Algebraic Equation
ANN	Artificial Neural Network
API	Active Pharmaceutical Ingredient
CHO	Chinese Hamster Ovary
DAE	Differential Algebraic Equation
IPOPT	Interior Point Optimizer
mAb	Monoclonal antibody
MRSA	Methicillin-Resistant <i>Staphylococcus Aureus</i>
NLP	Nonlinear Programming
ODE	Ordinary Differential Equation
UTI	Urinary Tract Infection
VRE	Vancomycin-Resistant <i>Enterococci</i>

Variables

Latin Letters

A_d	Death pre-exponent (-)
-------	------------------------

432	A_g	Growth pre-exponent (-)
433	CO	Dissolved oxygen concentration ($g L^{-1}$)
434	CO^*	Saturation dissolved oxygen concentration ($g L^{-1}$)
435	D	Fermentation vessel diameter (m)
436	d	Agitator diameter (m)
437	E_d	Energy barrier to death ($J mol^{-1}$)
438	E_g	Energy barrier to growth ($J mol^{-1}$)
439	F	Reactor feeding rate ($L hr^{-1}$)
440	g	Inequality constraint vector
441	g_f	Terminal inequality constraint vector
442	h	Equality constraint vector
443	h_f	Terminal equality constraint vector
444	K	Number of collocation points
445	K_1, K_2	Constants in Eq. 2
446	K_d	Monod constant ($g L^{-1}$)
447	K_h	Equilibrium constant (hr^{-1})
448	K_O	Contois saturation constant of dissolved oxygen (-)
449	K_S	Contois saturation constant of substrate (-)
450	K_{La}	Volumetric oxygen transfer coefficient (hr^{-1})
451	m_O	Maintenance coefficient of dissolved oxygen ($g g^{-1} hr^{-1}$)
452	m_S	Maintenance coefficient of substrate ($g g^{-1} hr^{-1}$)
453	MSE	Mean Squared Error
454	N	Number of control elements
455	n	Stirring rate (rpm)
456	P	Product concentration ($g L^{-1}$)
457	P_i	Stirring power (W)
458	Q	Fermentor ventilation volume ($m^3 hr^{-1}$)
459	R	Universal gas constant ($= 8.314 J mol^{-1}K^{-1}$)
460	S	Substrate concentration ($g L^{-1}$)
461	SSE	Sum of Squared Errors
462	T	Temperature (K)
463	t	Time (hr)
464	Δt	Time step (hr)
465	t_f	Final time (hr)
466	t_0	Initial time (hr)
467	u	Control variable vector
468	u_L	Control variable lower bound vector
469	u_U	Control variable upper bound vector
470	V	Fermentation broth volume (L)
471	V_F	Fermentor volume (L)
472	X	Biomass concentration ($g L^{-1}$)
473	x	State variable vector
474	X_{MAX}	Maximum biomass concentration ($g L^{-1}$)
475	x_L	State variable lower bound vector
476	x_0	State initial condition vector
477	x_U	State variable upper bound vector
478	$Y_{P/O}$	Yield constant of product vs. dissolved oxygen ($g g^{-1}$)
479	$Y_{P/S}$	Yield constant of product vs. substrate ($g g^{-1}$)
480	$Y_{X/O}$	Yield constant of biomass vs. dissolved oxygen ($g g^{-1}$)
481	$Y_{X/S}$	Yield constant of biomass vs. substrate ($g g^{-1}$)
482	<i>Greek Letters</i>	
483	β	Specific production rate ($g g^{-1} hr^{-1}$)
484	ϵ	Batch duration constraint (hr)
485	θ	Parameter vector
486	φ	Objective function
487	Ω_j	j^{th} -order polynomial
488	ψ_j	j^{th} -order Lagrange polynomial
489	μ_d	Specific death rate (hr^{-1})

490 μ_g Specific growth rate (hr^{-1})

491 References

- 492 1. Zaffiri, L.; Gardner, J.; Toledo-Pereyra, L.H. History of antibiotics. from salvarsan to cephalosporins. *J.*
493 *Investig. Surg.* **2012**, *25*, 67–77.
- 494 2. Russell, M.G.; Jamison, T.F. Seven-step continuous flow synthesis of linezolid without intermediate
495 purification. *Angew. Chemie Int. Ed.* **2019**, *58*, 7678–7681.
- 496 3. Lin, H.; Dai, C.; Jamison, T.F.; Jensen, K.F. A rapid total synthesis of ciprofloxacin hydrochloride in
497 continuous flow. *Angew. Chemie Int. Ed.* **2017**, *56*, 8870–8873.
- 498 4. Volpato, G.; Rodrigues, R.C.; Fernandez-Lafuente, R. Use of enzymes in the production of semi-synthetic
499 penicillins and cephalosporins: drawbacks and perspectives. *Curr. Med. Chem.* **2010**, *17*, 3855–3873.
- 500 5. Benazet, F.; Cartier, M.; Florent, J.; Godard, C.; Jung, G.; Lunel, J.; Mancy, D.; Pascal, C.; Renaut, J.; Tarridec,
501 P.; Theilleux, J.; Tissier, R.; Dubost, M.; Ninet, L. Nosiheptide, a sulfur-containing peptide antibiotic isolated
502 from *Streptomyces actuosus* 40037. *Experientia* **1980**, *36*, 414–416.
- 503 6. Wojtas, K.P.; Riedrich, M.; Lu, J.Y.; Winter, P.; Winkler, T.; Walter, S.; Arndt, H. D. Total synthesis of
504 nosiheptide. *Angew. Chemie - Int. Ed.* **2016**, *55*, 9772–9776.
- 505 7. Jolliffe, H.G.; Gerogiorgis, D.I. Technoeconomic optimization of a conceptual flowsheet for continuous
506 separation of an analgaesic active pharmaceutical ingredient (API). *Ind. Eng. Chem. Res.* **2017**, *56*, 4357–4376.
- 507 8. Gerogiorgis, D.I.; Jolliffe, H.G. Continuous pharmaceutical process engineering and economics.
508 Investigating technical efficiency, environmental impact + economic viability. *Chem. Today* **2015**, *33*, 29–32.
- 509 9. Yu, Y.; Duan, L.; Zhang, Q.; Liao, R.; Ding, Y.; Pan, H.; Wendt-Pienkowski, E.; Tang, G.; Shen, B.; Liu, W.
510 Nosiheptide biosynthesis featuring a unique indole side ring formation on the characteristic thiopeptide
511 framework. *ACS Chem. Biol.* **2009**, *4*, 855–864.
- 512 10. Shirahata, H.; Diab, S.; Sugiyama, H.; Gerogiorgis, D.I. Dynamic modelling, simulation and economic
513 evaluation of two CHO cell-based production modes towards developing biopharmaceutical
514 manufacturing processes. *Chem. Eng. Res. Des.* **2019**, *150*, 218–233.
- 515 11. Veterinary Antimicrobial Resistance and Sales Surveillance 2018
516 [https://www.gov.uk/government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-](https://www.gov.uk/government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-2018)
517 [2018](https://www.gov.uk/government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-2018) (accessed Mar 6, 2020).
- 518 12. Gonçalves, L.R.B.; Sousa, R.; Fernandez-Lafuente, R.; Guisan, J.M.; Giordano, R.L.C.; Giordano, R.C.
519 Enzymatic synthesis of amoxicillin: avoiding limitations of the mechanistic approach for reaction kinetics.
520 *Biotechnol. Bioeng.* **2002**, *80*, 622–631.
- 521 13. Gonçalves, L.R.B.; Giordano, R.L.C.; Giordano, R.C. Mathematical modeling of batch and semibatch
522 reactors for the enzymic synthesis of amoxicillin. *Process Biochem.* **2005**, *40*, 247–256.
- 523 14. Chow, Y.; Li, R.; Wu, J.; Pua, S.M.; New, S.W.; Chia, W.Q.; Lie, F.; Rahman, T.M.R.; Choi, W.J. Modeling
524 and optimization of methanol as a cosolvent in amoxicillin synthesis and its advantage over ethylene
525 glycol. *Biotechnol. Bioprocess Eng.* **2007**, *12*, 390–398.
- 526 15. Silva, J.A.; Costa Neto, E.H.; Adriano, W.S.; Ferreira, A.L.O.; Gonçalves, L.R.B. Use of neural networks in
527 the mathematical modelling of the enzymic synthesis of amoxicillin catalysed by penicillin G acylase
528 immobilized in chitosan. *World J. Microbiol. Biotechnol.* **2008**, *24*, 1761–1767.
- 529 16. McDonald, M.A.; Bommarius, A.S.; Rousseau, R.W.; Grover, M.A. Continuous reactive crystallization of β -
530 lactam antibiotics catalyzed by penicillin G acylase. Part I: Model development. *Comput. Chem. Eng.* **2019**,
531 *123*, 331–343.
- 532 17. McDonald, M.A.; Bommarius, A.S.; Grover, M.A.; Rousseau, R.W. Continuous reactive crystallization of β -
533 lactam antibiotics catalyzed by penicillin G acylase. Part II: Case study on ampicillin and product purity.
534 *Comput. Chem. Eng.* **2019**, *126*, 332–341.
- 535 18. Cuthbertson, A.B.; Rodman, A.D.; Diab, S.; Gerogiorgis, D.I. Dynamic modelling and optimisation of the
536 batch enzymatic synthesis of amoxicillin. *Processes* **2019**, *7*, 318–335.
- 537 19. Encarnación-Gómez, L.G.; Bommarius, A.S.; Rousseau, R.W. Crystallization kinetics of ampicillin using
538 online monitoring tools and robust parameter estimation. *Ind. Eng. Chem. Res.* **2016**, *55*, 2153–2162.
- 539 20. McDonald, M.A.; Bommarius, A.S.; Rousseau, R.W. Enzymatic reactive crystallization for improving
540 ampicillin synthesis. *Chem. Eng. Sci.* **2017**, *165*, 81–88.
- 541 21. Dafnomilis, A.; Diab, S.; Rodman, A.D.; Boudouvis, A.G.; Gerogiorgis, D.I. Multi-objective dynamic
542 optimization of ampicillin batch crystallization: sensitivity analysis of attainable performance vs. product
543 quality constraints. *Ind. Eng. Chem. Res.* **2019**, *58*, 18756–18771.
- 544 22. Schroën, C.G.P.H.; Nierstrasz, V.A.; Moody, H.M.; Hoogschagen, M.J.; Kroon, P.J.; Bosma, R.; Beertink,
545 H.H.; Janssen, A.E.M.; Tramper, J. Modeling of the enzymatic kinetic synthesis of cephalixin-influence of
546 substrate concentration and temperature. *Biotechnol. Bioeng.* **2001**, *73*, 171–178.

- 547 23. Schroën, C.G.P.H.; Fretz, C.B.; DeBruin, V.H.; Berendsen, W.; Moody, H.M.; Roos, E.C.; VanRoon, J.L.;
548 Kroon, P.J.; Strubel, M.; Janssen, A.E.M.; Tramper, J. Modelling of the enzymatic kinetically controlled
549 synthesis of cephalixin: influence of diffusion limitation. *Biotechnol. Bioeng.* **2002**, *80*, 331–340.
- 550 24. Travascio, P.; Zito, E.; De Maio, A.; Schroën, C.G.P.H.; Durante, D.; De Luca, P.; Bencivenga, U.; Mita, D.G.
551 Advantages of using non-isothermal bioreactors for the enzymatic synthesis of antibiotics: the penicillin G
552 acylase as enzyme model. *Biotechnol. Bioeng.* **2002**, *79*, 334–346.
- 553 25. McDonald, M.A.; Marshall, G.D.; Bommarius, A.S.; Grover, M.A.; Rousseau, R.W. Crystallization kinetics
554 of cephalixin monohydrate in the presence of cephalixin precursors. *Cryst. Growth Des.* **2019**, *19*, 5065–
555 5074.
- 556 26. Niu, D.; Jia, M.; Wang, F.; He, D. Optimization of nosiheptide fed-batch fermentation process based on
557 hybrid model. *Ind. Eng. Chem. Res.* **2013**, *52*, 3373–3380.
- 558 27. Niu, D.; Zhang, L.; Wang, F. Modeling and parameter updating for nosiheptide fed-batch fermentation
559 process. *Ind. Eng. Chem. Res.* **2016**, *55*, 8395–8402.
- 560 28. Farkya, S.; Bisaria, V.S.; Srivastava, A.K. Biotechnological aspects of the production of the anticancer drug
561 podophyllotoxin. *Appl. Microbiol. Biotechnol.* **2004**, *65*, 504–519.
- 562 29. Laursen, S.Ö.; Webb, D.; Ramirez, W.F. Dynamic hybrid neural network model of an industrial fed-batch
563 fermentation process to produce foreign protein. *Comput. Chem. Eng.* **2007**, *31*, 163–170.
- 564 30. Truppo, M.D.; Pollard, D.J.; Moore, J.C.; Devine, P.N. Production of (S)- γ -fluoro-leucine ethyl ester by
565 enzyme mediated dynamic kinetic resolution: comparison of batch and fed batch stirred tank processes to
566 a packed bed column reactor. *Chem. Eng. Sci.* **2008**, *63*, 122–130.
- 567 31. Xing, Z.; Bishop, N.; Leister, K.; Li, Z.J. Modeling kinetics of a large-scale fed-batch CHO cell culture by
568 Markov chain Monte Carlo method. *Biotechnol. Prog.* **2010**, *26*, 208–219.
- 569 32. Song, H.; Eom, M.H.; Lee, S.; Lee, J.; Cho, J.H.; Seung, D. Modeling of batch experimental kinetics and
570 application to fed-batch fermentation of *Clostridium tyrobutyricum* for enhanced butyric acid production.
571 *Biochem. Eng. J.* **2010**, *53*, 71–76.
- 572 33. Georgakis, C. Design of dynamic experiments: a data-driven methodology for the optimization of time-
573 varying processes. *Ind. Eng. Chem. Res.* **2013**, *52*, 12369–12382.
- 574 34. Kiparissides, A.; Pistikopoulos, E.N.; Mantalaris, A. On the model-based optimization of secreting
575 mammalian cell (GS-NS0) cultures. *Biotechnol. Bioeng.* **2015**, *112*, 536–548.
- 576 35. Robitaille, J.; Chen, J.; Jolicoeur, M. A single dynamic metabolic model can describe mAb producing CHO
577 cell batch and fed-batch cultures on different culture media. *PLoS One* **2015**, *10*, e0136815.
- 578 36. Ben Yahia, B.; Gourevitch, B.; Malphettes, L.; Heinzle, E. Segmented linear modeling of CHO fed-batch
579 culture and its application to large scale production. *Biotechnol. Bioeng.* **2017**, *114*, 785–797.
- 580 37. Raftery, J.P.; DeSessa, M.R.; Karim, M.N. Economic improvement of continuous pharmaceutical production
581 via the optimal control of a multifeed bioreactor. *Biotechnol. Prog.* **2017**, *33*, 902–912.
- 582 38. Kappatou, C.D.; Mhamdi, A.; Campano, A.Q.; Mantalaris, A.; Mitsos, A. Model-based dynamic
583 optimization of monoclonal antibodies production in semibatch operation—use of reformulation
584 techniques. *Ind. Eng. Chem. Res.* **2018**, *57*, 9915–9924.
- 585 39. Hogiri, T.; Tamashima, H.; Nishizawa, A.; Okamoto, M. Optimization of a pH-shift control strategy for
586 producing monoclonal antibodies in Chinese hamster ovary cell cultures using a pH-dependent dynamic
587 model. *J. Biosci. Bioeng.* **2018**, *125*, 245–250.
- 588 40. Kappatou, C.D.; Altunok, O.; Mhamdi, A.; Mantalaris, A.; Mitsos, A. Sequential and simultaneous
589 optimization strategies for increased production of monoclonal antibodies. *Comput.-Aided Chem. Eng.* **2019**,
590 *46*, 1021–1026.
- 591 41. Rodman, A.D.; Gerogiorgis, D.I. Multi-objective process optimisation of beer fermentation via dynamic
592 simulation. *Food Bioprod. Process.* **2016**, *100*, 255–274.
- 593 42. Rodman, A.D.; Gerogiorgis, D.I. Dynamic optimization of beer fermentation: sensitivity analysis of
594 attainable performance vs. product flavour constraints. *Comput. Chem. Eng.* **2017**, *106*, 582–595.
- 595 43. Biegler, L.T.; Cervantes, A.M.; Wächter, A. Advances in simultaneous strategies for dynamic process
596 optimization. *Chem. Eng. Sci.* **2002**, *57*, 575–593.
- 597 44. Biegler, L.T. An overview of simultaneous strategies for dynamic optimization. *Chem. Eng. Process. Process*
598 *Intensif.* **2007**, *46*, 1043–1053.
- 599 45. Rodman, A.D.; Fraga, E.S.; Gerogiorgis, D.I. On the application of a nature-inspired stochastic evolutionary
600 algorithm to constrained multi-objective beer fermentation optimisation. *Comput. Chem. Eng.* **2018**, *108*,
601 448–459.
- 602 46. Almeida, E.; Secchi, A.R. Dynamic optimization of a FCC converter unit: numerical analysis. *Brazilian J.*
603 *Chem. Eng.* **2011**, *28*, 117–136.
- 604 47. Osorio, D.; Pérez-Correa, R.; Belancic, A.; Agosin, E. Rigorous dynamic modeling and simulation of wine
605 distillations. *Food Control* **2004**, *15*, 515–521.

- 606 48. Farhat, S.; Czernicki, M.; Pibouleau, L.; Domenech, S. Optimization of multiple-fraction batch distillation
607 by nonlinear programming. *AIChE J.* **1990**, *36*, 1349–1360.
- 608 49. Mujtaba, I.M.; Macchietto, S. Optimal operation of multicomponent batch distillation-multi-period
609 formulation and solution. *Comput. Chem. Eng.* **1993**, *17*, 1191–1207.
- 610 50. Sørensen, E.; Macchietto, S.; Stuart, G.; Skogestad, S. Optimal control and on-line operation of reactive batch
611 distillation. *Comput. Chem. Eng.* **1996**, *20*, 1491–1498.
- 612 51. Cervantes, A.; Biegler, L.T. Large-scale DAE optimization using a simultaneous NLP formulation. *AIChE J.*
613 **1998**, *44*, 1038–1050.
- 614 52. Cervantes, A.M.; Wächter, A.; Tütüncü, R.H.; Biegler, L.T. A reduced space interior point strategy for
615 optimization of differential algebraic systems. *Comput. Chem. Eng.* **2000**, *24*, 39–51.
- 616 53. Logsdon, J.S.; Biegler, L.T. Accurate solution of differential-algebraic optimization problems. *Ind. Eng.*
617 *Chem. Res.* **1989**, *28*, 1628–1639.
- 618 54. Tanartkit, P.; Biegler, L.T. Stable decomposition for dynamic optimization. *Ind. Eng. Chem. Res.* **1995**, *34*,
619 1253–1266.
- 620 55. Rodman, A.D.; Gerogiorgis, D.I. An investigation of initialisation strategies for dynamic temperature
621 optimisation in beer fermentation. *Comput. Chem. Eng.* **2019**, *124*, 43–61.
- 622



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).